Family · Pharmaceutical analytical standards
Imrecoxib
A COX-2 inhibitor anti-inflammatory drug born in China from the research of Guo Zongru's group, approved and launched there in 2011 to relieve the pain of osteoarthritis. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?It was designed to inhibit COX-2 in only a 'moderately selective' way, less than the other coxibs and more than traditional NSAIDs, with the aim of preserving the balance between prostacyclin and thromboxane.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
